Potential drug for treating deadly brain cancer

September 4, 2012
Current therapies eradicate tumour cells initially but cancer stem cells may allow for tumours to recur. AntimiR-138 can destroy cancer stem cells and hence tumour growth.

(Medical Xpress)—A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults − glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour. The research findings were published on Aug 23 in the scientific journal, Cell Reports from Cell Press.

The scientists found that the biomarker, miR-138, is highly expressed in cancer stem cells compared to normal . They thus carried out in vitro experiments to deplete miR-138 in these cancer stem cells with a potential drug, antimiR-138, to observe the effect. They found that when miR-138 is depleted, the are completely destroyed. This is an important breakthrough as current therapies such as and surgical methods proved to be inadequate in treating these brain tumours, which tend to re-grow from cancer stem cells and become extremely lethal. 

Dr Sampath said, "In this study we have identified a master regulator, miR-138, which is essential for the progression and relapse of a deadly form of brain cancer. By targeting this regulator we can effectively prevent the recurrence of this lethal form of cancer. This promising finding will pave the way for the development of a to successfully treat the aggressive forms of brain cancer."

Studies were also done in mice to determine whether antimiR-138 could effectively inhibit the growth of tumours. These experiments were conducted with a control drug as well, revealing that tumours continued to be present when mice were injected with the control, while injection with the antimiR-138 showed no tumour growth after nine months.

Dr Alan Colman, Executive Director of Singapore Stem Cell Consortium and a Principal Investigator at IMB said, " are a particularly devastating and lethal form of cancer. As with a growing number of other cancers, evidence is accumulating that the persistence and chemo-resistance of this cancer is due to the presence of glioma stem cells (GSCs).  In this exciting publication, Sampath and colleagues indicate that in the tumours, these GSCs express the microRNA-138 (miR-138) and that the targeted elimination of this RNA markedly reduced the growth and survival of GSCs in cell culture.  This work highlights the possible significance of miR-138 as a prognostic biomarker and also suggests miR-138 synthesis as a target for therapeutic intervention."

Prof Sir David Lane, Chief Scientist at A*STAR, added, "These findings will facilitate the translation of basic research into clinical applications such as targeted drug design to treat brain cancer."

Explore further: To combat deadly brain cancer, target the stem cells

More information: Xin Hui Derryn Chan et al., "Targeting Glioma Stem Cells by Functional Inhibition of a Prosurvival OncomiR-138 in Malignant Gliomas". Cell Press. August 23.

Related Stories

To combat deadly brain cancer, target the stem cells

July 7, 2011
Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found ...

miR loss may power maligant transformation in chronic leukemia

July 5, 2012
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.